AU2013305580A1 - Anxiolytic composition, formulation and method of use - Google Patents

Anxiolytic composition, formulation and method of use Download PDF

Info

Publication number
AU2013305580A1
AU2013305580A1 AU2013305580A AU2013305580A AU2013305580A1 AU 2013305580 A1 AU2013305580 A1 AU 2013305580A1 AU 2013305580 A AU2013305580 A AU 2013305580A AU 2013305580 A AU2013305580 A AU 2013305580A AU 2013305580 A1 AU2013305580 A1 AU 2013305580A1
Authority
AU
Australia
Prior art keywords
nmda receptor
receptor antagonist
anxiety
administered
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013305580A
Other languages
English (en)
Inventor
Stuart L. Weg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2013305580A1 publication Critical patent/AU2013305580A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013305580A 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use Abandoned AU2013305580A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692380P 2012-08-23 2012-08-23
US61/692,380 2012-08-23
PCT/US2013/056424 WO2014031975A1 (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Publications (1)

Publication Number Publication Date
AU2013305580A1 true AU2013305580A1 (en) 2015-04-09

Family

ID=50148531

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013305580A Abandoned AU2013305580A1 (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Country Status (11)

Country Link
US (4) US20140057988A1 (enExample)
EP (2) EP2887930A4 (enExample)
JP (2) JP6722453B2 (enExample)
KR (1) KR20150096370A (enExample)
CN (1) CN104902883A (enExample)
AU (1) AU2013305580A1 (enExample)
BR (1) BR112015003796A2 (enExample)
IL (1) IL237340A0 (enExample)
MX (1) MX2015002378A (enExample)
SG (1) SG11201501292UA (enExample)
WO (1) WO2014031975A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX371392B (es) 2013-03-15 2020-01-28 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina.
US20140275277A1 (en) * 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
EP2983787B1 (en) 2013-04-12 2019-10-02 Icahn School of Medicine at Mount Sinai Method for treating post-traumatic stress disorder
ES2897453T3 (es) 2013-09-13 2022-03-01 Univ Chiba Nat Univ Corp Aplicación de R-ketamina y sal de la misma como productos farmacéuticos
EP3179993B1 (en) 2014-08-13 2021-01-20 Janssen Pharmaceutica NV Esketamine for use in a method for the treatment of depression
JP6757537B2 (ja) * 2014-08-29 2020-09-23 公益財団法人ヒューマンサイエンス振興財団 神経疾患モデル動物の製造方法及び神経疾患モデル動物
CA2961208A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
EP3085366A1 (en) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
JP2018521007A (ja) * 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN105249531A (zh) * 2015-08-06 2016-01-20 云南中烟工业有限责任公司 一种金丝楠木提取物的制备方法及其应用
ES2909329T3 (es) * 2015-09-08 2022-05-06 Childrens Hospital Philadelphia Activador no selectivo del receptor metabotrópico de glutamato para el tratamiento del trastorno de déficit de atención
EP3377050A4 (en) * 2015-11-17 2019-11-20 The Trustees of Columbia University in the City of New York PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
BR112020012473A2 (pt) 2017-12-22 2020-11-24 Janssen Pharmaceuticals, Inc. escetamina para o tratamento da depressão
PT3505157T (pt) 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
JP2021523228A (ja) 2018-05-04 2021-09-02 パーセプション ニューロサイエンス，インコーポレイティド 物質乱用の治療方法
WO2020041329A1 (en) * 2018-08-20 2020-02-27 Yale University Combination therapy for treating or preventing depression or other mood diseases
US12115601B2 (en) 2019-02-22 2024-10-15 Harima Chemicals, Incorporated Method of applying solid brazing material, method of producing coated workpiece, application apparatus, and roll-shaped solid brazing material
AU2020231172A1 (en) 2019-03-05 2021-09-23 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
WO2020232246A1 (en) * 2019-05-15 2020-11-19 The Trustees Of Columbia University In The City Of New York Compositions and methods against stress-induced affective disorders and their associated symptoms
US20220218627A1 (en) * 2019-05-31 2022-07-14 Lionheart Pharmaceuticals Aps Intranasal administration of ketamine to cluster headache patients
JP2023511370A (ja) 2020-01-22 2023-03-17 シーロス セラピューティクス， インコーポレイテッド Ｎｍｄａ拮抗薬の副作用の低減

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
AU2007229866A1 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
AU2008245662A1 (en) * 2007-04-26 2008-11-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder

Also Published As

Publication number Publication date
EP2887930A4 (en) 2016-03-23
EP3878442A1 (en) 2021-09-15
US20220160655A1 (en) 2022-05-26
EP2887930A1 (en) 2015-07-01
US20180235906A1 (en) 2018-08-23
JP2016501828A (ja) 2016-01-21
JP2018162302A (ja) 2018-10-18
WO2014031975A1 (en) 2014-02-27
SG11201501292UA (en) 2015-05-28
CN104902883A (zh) 2015-09-09
US20250255834A1 (en) 2025-08-14
JP6771512B2 (ja) 2020-10-21
KR20150096370A (ko) 2015-08-24
JP6722453B2 (ja) 2020-07-15
US20140057988A1 (en) 2014-02-27
MX2015002378A (es) 2015-09-25
BR112015003796A2 (pt) 2017-07-04
IL237340A0 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
US20250255834A1 (en) Anxiolytic composition, formulation and method of use
US5543434A (en) Nasal administration of ketamine to manage pain
Raval et al. Oral clonidine pre medication for attenuation of haemodynamic response to laryngoscopy and intubation
JP2009530385A (ja) うつ病の治療のためのケタミンの鼻内投与
MXPA96003633A (en) Use of ketamine and device for the nasal and eye administration of ketamine for the management of pain and for detoxification
EA006384B1 (ru) Композиция фентанила для интраназального введения
US20070066996A1 (en) Modafinil-based neurorehabilitation of impaired neurological function associated with brian injury
JP7705348B2 (ja) 睡眠時無呼吸を治療するための方法および組成物
Rewari et al. Remifentanil and propofol sedation for retrobulbar nerve block
TW200918048A (en) Drug combinations for the treatment of sialorrhoea
JP2016535027A (ja) 非角化重層上皮（ＮＫＳＥ）組織の不快感の治療用局所薬としての１−ジ（ｓｅｃ−ブチル）−ホスフィノイル−ペンタン（ＤＡＰＡ−２−５）
Esmat et al. Comparative study between transdermal nicotine and melatonin patches on postoperative pain relief after laparoscopic cholecystectomy, a double-blind, placebo-controlled trial
Mogahed et al. The effect of adding two different doses of magnesium sulphate as adjuvant to ropivacaine in peribulbar block for cataract surgery
Esmat et al. Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy, a double-blind, placebo-controlled trial
Mohamed et al. Fentanyl versus midazolam as additive to local anesthetic mixture for peribulbar block during posterior segment surgery in adult patients a prospective randomized double-blind study
Shan-su et al. Effects of intravenous infusion of esketamine on analgesia and postpartum antidepressant after cesarean section.
Busara Sirivanasandha et al. Recovery profiles after general anesthesia in patients undergoing anterior cervical discectomy and fusion (ACDF) surgery with or without dexmedetomidine as an anesthetic adjuvant: a double blinded randomized study
Yu et al. Transdermal fentanyl for management of cancer pain in elderly patients in China
Hosni et al. Efficacy of a premedication with melatonin during cataract surgery under peribulbar block: Study protocol for a prospective randomized double-blinded study
Black et al. Propofol-Ketamine Versus Propofol-Remifentanil in Office-Based Facial Plastic Surgery: Comparison of Postoperative Pain
Zanza et al. Effectiveness of Intranasal Analgesia in The Emergency
Tay et al. Knowing the Emergency Drugs in your Dental Practice
Wong et al. Sedation and Analgesia for HIFU Ablation
Ahuja A Comparitive Clinical Evaluation of Dexmedetomidine V/S Propofol in Patients Undergoing Extraction of Impacted Mandibular Third Molars
CN118526502A (zh) 腺苷酸环化酶抑制剂用于制备治疗围手术期疼痛药物的应用

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period